Catalog No.
DHH28803
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1
Concentration
6.17 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q16552 & Q96PD4
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CDP4940, UCB-4940, UCB4940, CAS: 1418205-77-2
Clone ID
Bimekizumab
[Psoriatic arthritis : Drugs of the (near) future], PMID: 28681115
A revolutionary therapeutic approach for psoriasis: bispecific biological agents, PMID: 27153320
An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far, PMID: 33727793
Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis, PMID: 33977094
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial, PMID: 33549192
Bimekizumab for Moderate-to-Severe Plaque Psoriasis, PMID: 34077151
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study, PMID: 32473974
Bimekizumab for the treatment of psoriatic disease, PMID: 30332893
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial, PMID: 32035552
Bimekizumab Offers Rapid and Durable Psoriasis Treatment, PMID: 33904869
Bimekizumab versus Adalimumab in Plaque Psoriasis, PMID: 33891379
Bimekizumab versus Secukinumab in Plaque Psoriasis, PMID: 33891380
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial, PMID: 33549193
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F, PMID: 32973785
Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis, PMID: 34384327
Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis, PMID: 31172372
Bimekizumab: the new drug in the biologics armamentarium for psoriasis, PMID: 34178093
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management, PMID: 33026212
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis, PMID: 33377312
Correction: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase llb, randomised, double blind, placebo-controlled, dose-ranging study, PMID: 32816784
Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis, PMID: 32844372
Developments with experimental and investigational drugs for axial spondyloarthritis, PMID: 28562100
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation, PMID: 29275332
Dual inhibition of IL-17A and IL-17F in psoriatic disease, PMID: 34408825
Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells, PMID: 32723833
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study, PMID: 32253184
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial, PMID: 29609013
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study, PMID: 31177099
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial, PMID: 34406364
Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials, PMID: 33432451
Emerging drugs for the treatment of axial spondyloarthritis, PMID: 29475394
Emerging systemic drugs in the treatment of plaque psoriasis, PMID: 32192366
Emerging treatment options for spondyloarthritis, PMID: 31171316
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum], PMID: 31616625
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential, PMID: 31214486
European League Against Rheumatism And American Diabetes Association, PMID: 27504068
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis, PMID: 27859546
IL-17 inhibition in axial spondyloarthritis: current and future perspectives, PMID: 30957574
Inhibition of interleukins 17A and 17F in psoriatic arthritis, PMID: 32035535
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules, PMID: 34239295
Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis, PMID: 31447673
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review, PMID: 32427307
Pharmacological development in hidradenitis suppurativa, PMID: 31075754
State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis, PMID: 31212119
Systematic review of immunomodulatory therapies for hidradenitis suppurativa, PMID: 31190730
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis, PMID: 31917873
The next quantum leap forward? Bimekizumab for psoriasis, PMID: 33549176
Treating to Target(s) With Interleukin-17 Inhibitors, PMID: 30742778
Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis, PMID: 32166932
For research use only. Not for human or drug use.
